CAS:73963-72-1 C20H27N5O2 Cilostazol

Min.Order / FOB Price:Get Latest Price

500 Gram	Negotiable

500 Gram

Negotiable

Min.Order :500 Gram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

CAS:73963-72-1 C20H27N5O2 Cilostazol CAS:73963-72-1 C20H27N5O2 factory price high purity 99% CAS:73963-72-1 C20H27N5O2 technical grade or OLED grade

Quick Details

Appearance:white poweder
Application:CAS:73963-72-1 C20H27N5O2 technical grade or OLED grade
PackAge:Plastic vacuum packaging bag or bucket
ProductionCapacity:1|Metric Ton|Day
Storage:under the cool and dry area
Transportation:by express or by sea

Superiority:

Cilostazol Basic information

Pharmacological effects Clinical application Adverse reactions Precautions Chemical Properties Application Production method

Product Name:	Cilostazol
Synonyms:	6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE;6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1h)-quinolinone additional name: 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone;CILASTAZOL;CILOSTAZOL;CILOSTAZOLE;RETAL;OPC 13013;OPC 21
CAS:	73963-72-1
MF:	C20H27N5O2
MW:	369.46
EINECS:
Product Categories:	Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals;API's;inhibitor;Cardiovascular APIs
Mol File:	73963-72-1.mol

Cilostazol Chemical Properties

mp	159-160°C
storage temp.	Store at RT
solubility	DMSO: 18 mg/mL, soluble
form	solid
color	off-white

Safety Information

Hazard Codes	Xi
WGK Germany	2
RTECS	VC8277500

MSDS Information

Provider	Language
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone Additional name: 6-[4-(1-Cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone	English
SigmaAldrich	English

Cilostazol Usage And Synthesis

Pharmacological effects	Cilostazol is commonly used clinically anti-platelet and anti-clotting drugs. It belongs to a phosphodiesterase inhibitor and can inhibit the activity of phosphodiesterase of platelet and smooth muscle cells, leading to increase of the cAMP concentration in platelets and vascular smooth muscle. It can significantly inhibit the platelet aggregation induced by various kinds of aggregation inducers, and can cause the dissociation of the aggregates. Its major metabolite, epoxide has a three to four fold activity of the prototype drug. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. Artery injection of this product can increase the blood flow rate with the strongest effect on the peripheral blood vessels but the weakest effect on the cerebral blood vessels. This product is rapidly absorbed in the intestine after oral administration with the Tmax being 3h, PPB being about 95%. Consecutive administration of four days by twice per day caused no increase in the plasma concentration accumulation. It has good tissue distribution with especially high level in the stomach, liver and kidney. At 72h after administration, 42.75% of the administered drug is excreted via urine and 61.7% is subject to fecal excretion. After 48 hour of administration, bile excretion rate is 31.7%. T1 / 2α is 2.2h and T1 / 2β is 18h.
Clinical application	It can be used to alleviate the ischemic symptom such as ulcers, limb pain, cold sensation and intermittent claudication caused by chronic arterial occlusive disease. It can also be applied to the adjuvant treatment of atherosclerosis, arteritis, thromboangiitis obliterans, diabetes-induced ischemia of extremity and takayasu arteritis. Cilostazol also be used as a complementary therapy after surgical treatment to help alleviate the symptoms, improve the circulation and inhibiting thrombosis in transplanted blood vessel.
Adverse reactions	There may be occasionally rash, hives, itching, palpitations, pulse frequency, low blood pressure, fever, dizziness, dizziness, vertigo, insomnia or drowsiness, swelling, pain, fatigue, weakness, stomach discomfort, nausea, vomiting, loss of appetite, diarrhea, upper abdominal pain, abdominal fullness, increased level of GOT (serum alanine aminotransferase), ALP (serum alkaline phosphatase), LDH (serum lactate dehydrogenase), BUN (blood urea nitrogen), creatinine and uric acid, gastrointestinal bleeding, epistaxis, subcutaneous bleeding, retinal hemorrhage, hematuria, bleeding tendencies and thrombocytopenia. The above information is edited by the chemicalbook of Dai Xiongfeng.
Precautions	Patients of hemophilia, capillary fragility syndrome, upper gastrointestinal bleeding and urinary tract bleeding as well as vitreous hemorrhage should be disabled. Women of pregnancy or possible pregnancy should be disabled. This product is should be taken cautious when being applied to patients in the use of anticoagulants (warfarin) or antiplatelet drugs (aspirin, Ticlid) patients. When using cilostazol, the patients should be subject to blood coagulation performance test. Women in menstrual period, patients of bleeding tendency or with severe hepatic and renal dysfunction as well as elderly should administer with caution; breast-feeding women should avoid breast-feeding.
Chemical Properties	It is colorless, needle-like crystals obtained from methanol with the m.p. being 159.4 ~ 160.3 ℃ and the UV absorption maximum (methanol) being 257nm (ε15200). It is easily soluble in acetic acid, chloroform, N- methyl-2-pyrrolidone or dimethyl sulfoxide and almost insoluble in ether, water, 0.1mol / L hydrochloric acid or 0.1mol / L sodium hydroxide.
Application	It can significantly inhibit the platelet aggregation caused by various inducers and aggregates and can dissociate the aggregates without causing secondary aggregation. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. It can also be used for treating ischemic diseases such as chronic arterial occlusive ulcer, pain and coldness.
Production method	Take 5-chloro-N-cyclohexyl pentanamide as the raw material. Under ice-cooling, to 15 mL of benzene solution containing 1.75g ??5- chloro -N- cyclohexyl-pentyl amide solution, slowly add 1.9 g of phosphorus pentachloride and stir at room temperature for 1h. At room temperature and stirring, add 1.4mol/L HN3 to 1 mL of the benzene solution. After stirring overnight, continue the reflux for 2h. The solvent was distilled off under reduced pressure with the residue being poured into ice water and subject to chloroform extraction. The extract was successively washed with water, dilute sodium bicarbonate solution and water, further dried by anhydrous sodium sulfate. After the chloroform was distilled off, the residue was subject to isopropanol - water recrystallization to obtain 1.7 g of 5- (4-chlorobutyl) -l-cyclohexyl-tetrazole, being as colorless needle-like crystals with the yield being 87% and the m.p. being 48 -49 ℃. Dissolve 3.2 g 6-hydroxy-3, 4-dihydrogen-2(1H)-quinolinone and 1.4 g of potassium hydroxide in 20 mL of isopropanol. Under reflux, add drop wise of the isopropanol solution containing 5.7 g of the tetrazole obtained above. Continue stirring and reflux for 4h. Evaporate to dryness with the residue being extracted with chloroform. The extract was washed with l mol / L sodium hydroxide solution, dilute hydrochloric acid and water, dried by anhydrous sodium sulfate. Chloroform was distilled off with the residual liquid being subject to chromatograph on silica gel. Use chloroform - methanol (30: 1) for elution. Then apply methanol - water recrystallization to obtain 6.0 g of colorless needles cilostazol with the yield being 74% and the melting point being 158 ??~ 159 ℃.
Chemical Properties	Colourless Needles
Usage	A potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake. Has antimitogeni, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo
Usage	antibacterial; LD50(iv) 280mg/kg(mouse)
Biological Activity	Potent phosphodiesterase III A (PDE3A) inhibitor (IC 50 = 0.2 μ M) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo . Also affects lipid levels in vivo .

Cilostazol Preparation Products And Raw materials

Raw materials

Sodium sulfate-->Phosphorus pentachloride-->Water-->Tetrazole-->1,2,3,4-Tetrahydroquinolin-2-one-->Pentanamide

Our Services

1.Certificate Of Analysis (COA)

2.Material Safety Data Sheet (MSDS)

3.Route of synthesis (ROS)

4.Method of Aanlysis (MOA)

5.Nuclear Magnetic Resonance (NMR)

6.Packing pictures and loading video before loading

7.Free Sample

9.Factory audit

10.Strong after-sale service

Details:

Name: Valsartan

Chemical name: 3,5-Diiodo-4-Pyridone N-(1-Oxopentyl)-N-{[2'-(1H-tetrazol-5-yl-1,1'-biphenyl)-4-yl]methyl}-L-valine
CAS No. :137862-53-4
Molecular formula: C₂₄H₂₉N₅O₃
Molecular weight: 435.53
Properties: It is white powder;tasteless.
Related substance：≤2.0％
Water≤2.0％
Residual ignition≤0.1％

View All

Visit Store

CAS:73963-72-1 C20H...